Sagimet Biosciences Inc. 8-K

What Happened
Sagimet Biosciences, Inc. (SGMT) filed a Form 8‑K on May 12, 2026 under Item 2.02 to announce its financial results for the quarter ended March 31, 2026. The company furnished a press release dated May 12, 2026 as Exhibit 99.1 to the filing; the press release contains the detailed quarterly results (earnings, revenue and other financial metrics).

Key Details

• Filing date: May 12, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: quarter ended March 31, 2026.
• Press release: furnished as Exhibit 99.1 and incorporated by reference in the 8‑K.
• Machine-readable data: Inline XBRL cover page (Exhibit 104) is included in the filing.

Why It Matters
This 8‑K signals that Sagimet has publicly released its quarterly results—important for investors tracking earnings, revenue, cash position and near‑term operational progress. The Form 8‑K itself does not include line‑by‑line financial tables; investors should review the May 12, 2026 press release (Exhibit 99.1) and any related SEC filings for the full financial details and context before making investment decisions.